دانلود رایگان مقاله انگلیسی افزایش فشار خون ریوی: جنبه های مولکولی مداخله درمانی - وایلی 2017

Abstract

Pulmonary hypertension (PH) is a life-threatening lung disorder with towering prevalence and risk for future has been gradually rising worldwide. Even, no specific medications are available for pulmonary hypertension; various classes of treatment based upon the origin and magnitude of hypertension are still used for the treatment of PH. Consideration of molecular or signaling modulation is the imperative approach that can offer a new notion for prevalent pharmacotherapeutic agents. Instead of concurrent targets, including endothelin receptor antagonists (ETA/ETB), phosphodiesterase 5 inhibitor (PDF-5), calcium channel blockers, anticoagulants, diuretics and long acting prostacyclin analogue, recent scientific reports revealed the numerous potential alternative therapeutic approaches that can significantly target the pathological signaling alteration associated with PH. Understanding precise molecular cascade involved in PH can be useful for designing preclinical animal experiments and human clinical trials to evaluate target specific novel therapeutic interventions for the treatment of PH. In this review, we discussed the possible molecular signaling involved in the pathogenesis of PH and detailed account of the current status of medications employed for the treatment of PH. Moreover, the newly identified potential target sites and alternative approaches for treating the PH have been discussed. This article is protected by copyright.

Conclusion

Molecular interaction of therapeutic interventions to modify the pathological events have been an inimitable method of research to update the endured treatment into advanced. PH is endorsed by several signaling alteration including IP3/DAG, Kv channel, NADPH oxidase, PI3 kinase, Rho kinase, MAP kinase, Ca2+ channel, PDGF, PDE, PPAR, HMG-Co A- reductase, endothelin signaling pathways. Instead of PH, these avenues of abnormality in molecular signaling make it more vulnerable to atherosclerosis, hypertension, coronary heart disease and pulmonary endothelial damage. The present review demonstrated the several targeted links and molecular aspects of various therapeutic interventions having an association with signaling alteration of PH mediated by vascular endothelial dysfunction. Moreover, various alternative therapeutic interventions including Panax ginseng (Araliaceae), Genistein, Salvia Miltiorrhiza (Lamiaceae), Chinese herb Naofeikang, Radix Astragali (Fabaceae), Allium sativum (Amaryllidaceae) Luteolin (Lamiaceae), Rhoifolin (Rutaceae), Punicalagin (Punica granatum), Erigeron breviscapus (Asteraceae) and Terminalia Arjuna (Combretaceae) also have significant competence to modify these signaling alteration. and may open the new possibility of novel signaling modulator which can restore the pathological events and improve PH.